⌘K

/

/

Accelerating fibrosis and inflammation research through validated preclinical models and expert insights.

Research

モデル
薬剤
インサイト

Company

CROパートナー
Contact Us
Privacy Policy

© 2025 Fibrosis-Inflammation Lab. All rights reserved.

Privacy Policy Terms of Service

Denifanstat (Denifanstat) | 加速させる、線維化研究を

Home/Drugs/Denifanstat

Denifanstat

Denifanstat

Phase 3

Sponsor: Sagimet Biosciences

Indication: MASH

Mechanism of Action

FASN Inhibitor

Target: FASN

Clinical Information

Approval Year

Clinical Trials (ClinicalTrials.gov)

COMPLETEDNCT05835180

A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function

Phase:PHASE1Org:Sagimet Biosciences Inc.

WITHDRAWN

Relevant Publications (PubMed)

No recent publications found for Denifanstat.

Validated Models

This drug has been validated in the following preclinical models:

NCT06692283

A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH

Phase:PHASE3Org:Sagimet Biosciences Inc.

WITHDRAWNNCT06594523

A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 Fibrosis

Phase:PHASE3Org:Sagimet Biosciences Inc.

COMPLETEDNCT06192264

A Study to Evaluate the Safety and Efficacy of ASC40 (Denifanstat) Tablets in the Treatment of Patients With Moderate to Severe Acne Vulgaris

Phase:PHASE3Org:Ascletis Pharma Inc

ACTIVE_NOT_RECRUITINGNCT07216313

A Drug-Drug Interaction Study of Denifanstat and Resmetirom in Healthy Adult Participants

Phase:PHASE1Org:Sagimet Biosciences Inc.

View all trials on ClinicalTrials.gov